Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...
A new orchestration approach, called Orchestral, is betting that enterprises and researchers want a more integrated way to ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Condé Nast Traveler readers believe this major US city is the end-all-be-all for shopping destinations in the country.